Pear Therapeutics, a leader in prescription digital therapeutics (PDT), announced the publication of real-world data on the use of its reset-O cognitive behavioral therapy applications.
The data, published in the Journal of Current Medical Research and Opinion, looked at more than 3,000 patients using reSET-O, the first FDA-approved Prescription Digital Therapeutic intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy as an adjunct of outpatient treatment and contingency management.
“We are excited to share these data as we believe this is an important confirmation of the potential for reSET-O to improve clinical outcomes at scale and address the unmet needs of OUD treatment,” said Yuri Maricich, M.D., Chief Medical Officer at Pear Therapeutics and lead author of the paper. “This cohort of patients represents one of the largest datasets of community OUD treatment analyzed to date and robustly demonstrates the real-world impact of a PDT integrated into standard of care for patients with OUD.”
The company said the analysis of patient engagement and use of reset-O and OUD outcomes, and found that the prescription digital therapeutic is potentially a valuable tool to use for patients getting medication-assisted treatment for OUD.
Prescription digital therapeutics use software to treat diseases. Like traditional medicines, the software has to be tested in randomized controlled trials and evaluated by the FDA. But unlike traditional medicines, PDTs are designed to collect real-world data for use that can be used by clinicians and others.
The study looked at 3,144 patients with OUD in a 12-week treatment program from 30 different states between the ages of 19 and over 60. The study found that 80 percent of the patients completed at least 25 percent of the core behavioral treatment modules, while 66 percent completed at least half of the behavioral modules, and 49 percent completed all of the modules. Research indicated that 70 percent of patients stuck with the treatment and continued the PDT during the last four weeks of the treatment. And of those using four or more PDT modules per week for the first four weeks, 88.1 percent remained abstinent for the last four weeks.